Glimepirid Sandoz (Glimepiride)

Glimepirid Sandoz is indicated for the treatment of type 2 diabetes mellitus in adults when diet, exercise, and lifestyle changes alone do not achieve adequate glycemic control.

• Used as monotherapy in patients with mild to moderate hyperglycemia.
• Added to metformin when single‑agent therapy is insufficient.
• May be combined with other oral antidiabetics such as DPP‑4 inhibitors.
• Considered for patients who can benefit from increased endogenous insulin secretion.
• Integrated into individualized treatment plans alongside diet and exercise.

The safety profile of Glimepirid Sandoz includes both frequently observed and less common adverse reactions that clinicians monitor during therapy.

Common

• Mild hypoglycemia, especially if meals are missed.
• Weight gain due to increased insulin activity.
• Nausea or gastrointestinal discomfort.
• Headache or dizziness.

Serious

• Severe hypoglycemia requiring assistance.
• Allergic skin reactions such as rash or urticaria.
• Hepatic dysfunction indicated by elevated liver enzymes.
• Hematologic abnormalities like leukopenia.

Before initiating Glimepirid Sandoz, healthcare providers should assess patient-specific factors and educate patients about potential risks associated with sulfonylurea therapy.

• Avoid use in patients with known hypersensitivity to glimepiride or sulfonylureas.
• Caution in individuals with renal or hepatic impairment; dose adjustment may be required.
• Monitor elderly patients closely due to increased risk of prolonged hypoglycemia.
• Do not use during pregnancy or breastfeeding unless benefits outweigh risks.
• Assess for cardiovascular disease, as sulfonylureas may affect cardiac ischemic preconditioning.
• Review concomitant use of alcohol, which can potentiate hypoglycemic episodes.

Glimepirid Sandoz can interact with several medicines, altering blood glucose levels or increasing the likelihood of adverse effects; clinicians should review patient medication lists.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which can cause additive hypoglycemia.
• Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which may raise glimepiride plasma concentrations.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose.
• ACE inhibitors or ARBs, requiring monitoring of renal function.
• Antidepressants like SSRIs that may affect glycemic control.